Evidence map›Paper›PMID 34914039›Full record

ArticleIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2021

Endoscopic sleeve gastroplasty - minimally invasive treatment for non-alcoholic fatty liver disease and obesity.

Nitin Jagtap, Rakesh Kalapala, Abhishek Katakwar, Mithun Sharma, Mohsin Aslam, Rajesh Gupta, P Nagaraja Rao, Rajesh Goud, Manu Tandan, Haranath Kanakagiri and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 7 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 7 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Review
  9. Endoscopy for Metabolic Diseases.Journal of clinical medicine · 2026
    Review
  10. Review
  11. Endoscopic sleeve gastrectomyWorld journal of gastrointestinal pharmacology and therapeutics · 2025
    Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Endobariatric systems: Strategic integration of endoscopic therapies in the management of obesity.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024
    Review
  17. Metabolic and Bariatric Endoscopy: A Mini-Review.Life (Basel, Switzerland) · 2023
    Review
  18. Review
  19. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Nitin JagtapDepartment of Medical Gastroenterology and Hepatology, Asian Institute of Gastroenterology, Hyderabad, 500 082, India. docnits13@gmail.com.ORCID http://orcid.org/0000-0002-3469-0164
Rakesh KalapalaDepartment of Medical Gastroenterology and Hepatology, Asian Institute of Gastroenterology, Hyderabad, 500 082, India.
Abhishek KatakwarDepartment of Metabolic and Bariatric Surgery, Asian Institute of Gastroenterology, Hyderabad, 500 082, India.
Mithun SharmaDepartment of Medical Gastroenterology and Hepatology, Asian Institute of Gastroenterology, Hyderabad, 500 082, India.
Mohsin AslamDepartment of Medical Gastroenterology and Hepatology, Asian Institute of Gastroenterology, Hyderabad, 500 082, India.
Rajesh GuptaDepartment of Medical Gastroenterology and Hepatology, Asian Institute of Gastroenterology, Hyderabad, 500 082, India.
P Nagaraja RaoDepartment of Medical Gastroenterology and Hepatology, Asian Institute of Gastroenterology, Hyderabad, 500 082, India.
Rajesh GoudDepartment of Medical Gastroenterology and Hepatology, Asian Institute of Gastroenterology, Hyderabad, 500 082, India.
Manu TandanDepartment of Medical Gastroenterology and Hepatology, Asian Institute of Gastroenterology, Hyderabad, 500 082, India.
Haranath KanakagiriDepartment of Anesthesiology, Asian Institute of Gastroenterology, Hyderabad, 500 082, India.
Santosh DarishettyDepartment of Anesthesiology, Asian Institute of Gastroenterology, Hyderabad, 500 082, India.
D Nageshwar ReddyDepartment of Medical Gastroenterology and Hepatology, Asian Institute of Gastroenterology, Hyderabad, 500 082, India.
Asian Institute of Gastroenterology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAdequate weight loss can lead to reduction in steatosis, inflammation, and fibrosis in patients with obesity and non-alcoholic fatty liver disease (NAFLD). We evaluated the role of endoscopic sleeve gastroplasty (ESG) in patients with obesity and NAFLD.

methodsIn this single-center prospective study, consecutive adult patients with NAFLD who underwent ESG between November 2018 and May 2019 were included. The primary outcome was the impact of ESG on hepatic parameters: change in alanine aminotransferase (ALT), hepatic steatosis index (HSI), NAFLD fibrosis score (NFS), fibrosis-4 index (FIB-4), and aspartate aminotransferase (AST)-to-platelet ratio index (APRI) from baseline to 6 and 12 months. Secondary outcomes included change in glycated hemoglobin (HbA1c), percentage weight loss, and safety. Analysis of variance with repeated measures was used for statistical analysis.

resultsA total of 26 patients (mean age [SD] 41.5 [9.58] years; 16 females) with mean (SD) weight of 99.43 (21.89) kg at baseline were included. There was significant improvement in ALT (mean ± SD) from baseline of 59.54 ± 17.02 IU/L to 49.50 ± 11.72 IU/L and 48.42 ± 13.22 IU/L at 6 and 12 months (p = 0.001). Mean (SD) NFS was significantly improved from 0.228 (1.00) at baseline to -0.202 (1.16) and -0.552 (1.08) at 6 and 12 months (p 0.001). Mean (SD) HSI, FIB-4, and APRI scores significantly reduced from baseline to 6 and 12 months (p = 0.001). There was 18.07% total body weight loss at 12 months, with significant improvement in HbA1c. There were no major adverse events.

conclusionESG is a safe and effective treatment option for patients with NAFLD and obesity causing significant weight loss. Rigorous randomized trials are required to incorporate ESG in NAFLD treatment algorithm.

Indexed as

GastroplastyNon-alcoholic Fatty Liver DiseaseAdultFemaleFibrosisGlycated HemoglobinHumansMaleMiddle AgedObesityProspective StudiesTreatment OutcomeWeight LossGlycated HemoglobinBariatric endoscopyDiabetes mellitusEndoscopic bariatric and metabolic therapiesEndoscopic sleeve gastroplastyFatty liverFibrosisInsulin resistanceMetabolic syndromeNon-alcoholic steatohepatitisSafetyTreatmentWeight loss

Identifiers

PMID34914039
OpenAlexW4200571306

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.